Assessing the role of Chemokine (C–C motif) ligand 14 in AKI: a European consensus meeting
Background Urinary Chemokine (C–C motif) ligand 14 (CCL14) is a biomarker associated with persistent severe acute kidney injury (AKI). There is limited data to support the implementation of this AKI biomarker to guide therapeutic actions.Methods Sixteen AKI experts with clinical CCL14 experience par...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2345747 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591104378142720 |
|---|---|
| author | Jay L. Koyner Christian Arndt Jaume Baldira Martinez de Irujo Sílvia Coelho Manuel Garcia-Montesinos de la Peña Luca di Girolamo Michael Joannidis Pablo Jorge-Monjas Christian Koch Steven Lobaz Alain Meyer Marlies Ostermann Nicoletta Pertica John R. Prowle Jon Silversides Alexander Zarbock Jorge Echeverri Kai Harenski Lui G. Forni |
| author_facet | Jay L. Koyner Christian Arndt Jaume Baldira Martinez de Irujo Sílvia Coelho Manuel Garcia-Montesinos de la Peña Luca di Girolamo Michael Joannidis Pablo Jorge-Monjas Christian Koch Steven Lobaz Alain Meyer Marlies Ostermann Nicoletta Pertica John R. Prowle Jon Silversides Alexander Zarbock Jorge Echeverri Kai Harenski Lui G. Forni |
| author_sort | Jay L. Koyner |
| collection | DOAJ |
| description | Background Urinary Chemokine (C–C motif) ligand 14 (CCL14) is a biomarker associated with persistent severe acute kidney injury (AKI). There is limited data to support the implementation of this AKI biomarker to guide therapeutic actions.Methods Sixteen AKI experts with clinical CCL14 experience participated in a Delphi-based method to reach consensus on when and how to potentially use CCL14. Consensus was defined as ≥ 80% agreement (participants answered with ‘Yes’, or three to four points on a five-point Likert Scale).Results Key consensus areas for CCL14 test implementation were: identifying challenges and mitigations, developing a comprehensive protocol and pairing it with a treatment plan, and defining the target population. The majority agreed that CCL14 results can help to prioritize AKI management decisions. CCL14 levels above the high cutoff (> 13 ng/mL) significantly changed the level of concern for modifying the AKI treatment plan (p < 0.001). The highest level of concern to modify the treatment plan was for discussions on renal replacement therapy (RRT) initiation for CCL14 levels > 13 ng/mL. The level of concern for discussion on RRT initiation between High and Low, and between Medium and Low CCL14 levels, showed significant differences.Conclusion Real world urinary CCL14 use appears to provide improved care options to patients at risk for persistent severe AKI. Experts believe there is a role for CCL14 in AKI management and it may potentially reduce AKI-disease burden. There is, however, an urgent need for evidence on treatment decisions and adjustments based on CCL14 results. |
| format | Article |
| id | doaj-art-753d3b3df1444924a5f6e8fcdb5753a2 |
| institution | Kabale University |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-753d3b3df1444924a5f6e8fcdb5753a22025-01-23T04:17:48ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492024-12-0146110.1080/0886022X.2024.2345747Assessing the role of Chemokine (C–C motif) ligand 14 in AKI: a European consensus meetingJay L. Koyner0Christian Arndt1Jaume Baldira Martinez de Irujo2Sílvia Coelho3Manuel Garcia-Montesinos de la Peña4Luca di Girolamo5Michael Joannidis6Pablo Jorge-Monjas7Christian Koch8Steven Lobaz9Alain Meyer10Marlies Ostermann11Nicoletta Pertica12John R. Prowle13Jon Silversides14Alexander Zarbock15Jorge Echeverri16Kai Harenski17Lui G. Forni18Section of Nephrology, Department of Medicine, University of Chicago, Chicago, IL, USAAnesthesiology and Intensive Care Medicine, Philipps-Universitat Marburg Fachbereich Medizin, Marburg, GermanyDepartment of Critical Care Medicine, Hospital Sant Pau, Barcelona, SpainIntensive Care Department, Hospital Fernando da Fonseca EPE, Amadora, PortugalDepartment of Intensive Care, Navarra University Hospital, Navarra, SpainDepartment of Anesthesia, Critical Care and Emergency, IRCCS Policlinico San Donato, Milan, ItalyDivision of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical Unversity Innsbruck, Innsbruck, AustriaAnesthesiology and Critical Care Department, Clinic University Hospital of Valladolid, Valladolid, SpainDepartment of Anesthesiology, Operative Intensive Care Medicine and Pain Therapy, Justus Liebig University of Giessen, Giessen, GermanyAnaesthetics and Intensive Care, Barnsley Hospital NHS Foundation Trust, Barnsley, UKPhysiology and Functional Exploration Service, University Hospital of Strasbourg, Strasbourg, FranceDepartment of Critical Care & Nephrology, King’s College London, Guy’s & St Thomas’ Hospital, London, UKDivision of Nephrology, Department of Biomedical and Surgical Sciences, University Hospital of Verona, Verona, ItalyCritical Care & Perioperative Medicine Research Group, William Harvey Research Institute, Queen Mary University of London, London, UKWellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast, UKDepartment of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, GermanyBaxter Healthcare Corporation, Deerfield, IL, USABaxter Deutschland GmbH, Unterschleissheim, GermanyCritical Care Unit, Royal Surrey Hospital and School of Medicine, University of Surrey, Guildford, UKBackground Urinary Chemokine (C–C motif) ligand 14 (CCL14) is a biomarker associated with persistent severe acute kidney injury (AKI). There is limited data to support the implementation of this AKI biomarker to guide therapeutic actions.Methods Sixteen AKI experts with clinical CCL14 experience participated in a Delphi-based method to reach consensus on when and how to potentially use CCL14. Consensus was defined as ≥ 80% agreement (participants answered with ‘Yes’, or three to four points on a five-point Likert Scale).Results Key consensus areas for CCL14 test implementation were: identifying challenges and mitigations, developing a comprehensive protocol and pairing it with a treatment plan, and defining the target population. The majority agreed that CCL14 results can help to prioritize AKI management decisions. CCL14 levels above the high cutoff (> 13 ng/mL) significantly changed the level of concern for modifying the AKI treatment plan (p < 0.001). The highest level of concern to modify the treatment plan was for discussions on renal replacement therapy (RRT) initiation for CCL14 levels > 13 ng/mL. The level of concern for discussion on RRT initiation between High and Low, and between Medium and Low CCL14 levels, showed significant differences.Conclusion Real world urinary CCL14 use appears to provide improved care options to patients at risk for persistent severe AKI. Experts believe there is a role for CCL14 in AKI management and it may potentially reduce AKI-disease burden. There is, however, an urgent need for evidence on treatment decisions and adjustments based on CCL14 results.https://www.tandfonline.com/doi/10.1080/0886022X.2024.2345747Biomarker testing experienceC‑C motif chemokine ligand 14 (CCL14)consensuscritical care nephrologypersistent acute kidney injury |
| spellingShingle | Jay L. Koyner Christian Arndt Jaume Baldira Martinez de Irujo Sílvia Coelho Manuel Garcia-Montesinos de la Peña Luca di Girolamo Michael Joannidis Pablo Jorge-Monjas Christian Koch Steven Lobaz Alain Meyer Marlies Ostermann Nicoletta Pertica John R. Prowle Jon Silversides Alexander Zarbock Jorge Echeverri Kai Harenski Lui G. Forni Assessing the role of Chemokine (C–C motif) ligand 14 in AKI: a European consensus meeting Renal Failure Biomarker testing experience C‑C motif chemokine ligand 14 (CCL14) consensus critical care nephrology persistent acute kidney injury |
| title | Assessing the role of Chemokine (C–C motif) ligand 14 in AKI: a European consensus meeting |
| title_full | Assessing the role of Chemokine (C–C motif) ligand 14 in AKI: a European consensus meeting |
| title_fullStr | Assessing the role of Chemokine (C–C motif) ligand 14 in AKI: a European consensus meeting |
| title_full_unstemmed | Assessing the role of Chemokine (C–C motif) ligand 14 in AKI: a European consensus meeting |
| title_short | Assessing the role of Chemokine (C–C motif) ligand 14 in AKI: a European consensus meeting |
| title_sort | assessing the role of chemokine c c motif ligand 14 in aki a european consensus meeting |
| topic | Biomarker testing experience C‑C motif chemokine ligand 14 (CCL14) consensus critical care nephrology persistent acute kidney injury |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2345747 |
| work_keys_str_mv | AT jaylkoyner assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT christianarndt assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT jaumebaldiramartinezdeirujo assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT silviacoelho assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT manuelgarciamontesinosdelapena assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT lucadigirolamo assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT michaeljoannidis assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT pablojorgemonjas assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT christiankoch assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT stevenlobaz assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT alainmeyer assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT marliesostermann assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT nicolettapertica assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT johnrprowle assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT jonsilversides assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT alexanderzarbock assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT jorgeecheverri assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT kaiharenski assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting AT luigforni assessingtheroleofchemokineccmotifligand14inakiaeuropeanconsensusmeeting |